TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A study of 575 GLP-1 receptor agonist users found higher reported rates of nail lifting and discoloration than among 1,329 people with obesity and/or type 2 diabetes who had never used the drugs. However, an analysis of nail problems that began after treatment started found no difference, so the findings show an association, not proof that GLP-1 drugs cause nail changes.
A study presented at a European dermatology meeting found that people taking GLP-1 receptor agonists reported more nail disorders, including onycholysis—separation of a nail from its nail bed—than a comparison group with obesity and/or type 2 diabetes who had never used the drugs. But an analysis restricted to nail changes that began after treatment started found no difference between groups, leaving it unclear whether the medications cause the problems.
The prospective study compared 575 GLP-1 users with 1,329 non-users recruited in France, the United States, Brazil and Mexico. Onycholysis was reported by 39.3% of drug users and 8.7% of non-users, a 4.5-fold difference in prevalence. Nail discoloration, or dyschromia, was reported by 45.6% and 17.0%, respectively, a 2.7-fold difference. Fragile nails and ridges or grooves were also more common among users.
Overall, 66.3% of GLP-1 users reported at least one type of nail disorder, compared with 52.8% of non-users; the difference was statistically significant (P<0.001). Analyses that accounted for factors such as age, sex, country and other health conditions continued to show higher likelihoods of onycholysis and discoloration among users. The supplied report describes those adjusted associations as roughly two to three times higher, while noting that results varied across analyses.
However, nearly half of the GLP-1 users said they had a history of nail problems before beginning treatment. When researchers examined only new-onset nail lesions, they found no difference in onycholysis or discoloration between users and non-users. The study relied on an online survey and self-reported nail changes rather than examinations by dermatologists, according to the report.
What the Nail Findings Mean
The results raise a possible side effect for people using GLP-1 medicines, but they do not establish that the drugs caused nail separation or discoloration. The gap in overall prevalence may reflect differences between the groups, existing nail problems or other health and nutritional factors, as well as a possible medication effect.
That distinction matters for patients weighing the benefits and risks of treatment. Dermatologist Joe Tung, who was not involved in the research, told MedPage Today that the findings should not prompt people who are doing well on a GLP-1 medication to stop it. He said common nail conditions can have treatable causes and encouraged people who notice changes to consult a dermatologist. The study authors said the signal warrants further research, not a conclusion about direct harm.
nail health supplements for brittle nails
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Researchers Compared Groups
GLP-1 receptor agonists are used in the treatment of type 2 diabetes and obesity. The study compared people taking the drugs with people who had obesity and/or diabetes but had never taken a GLP-1 medicine. The control group was older on average—56.7 years versus 45.3 years among users—although the distribution by sex was approximately even in both groups.
Lead researcher Bianca Maria Piraccini, of the University of Bologna, presented the findings at a meeting of the European Academy of Dermatology and Venereology in Vienna. Co-investigator Charles Taieb said nail changes linked to GLP-1 therapies had previously been reported mainly anecdotally. Piraccini also said the team considered other potential causes, including trauma and fungal infection, but the source report does not provide details sufficient to assess how those causes were ruled out across participants.
“Our findings show a clear association, but they also underline an important point: Not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself.”
— Charles Taieb, study co-investigator
As an affiliate, we earn on qualifying purchases.
Cause and Timing Remain Unsettled
The central uncertainty is whether GLP-1 medicines contribute directly to nail changes. The higher rates appeared in analyses of all reported nail problems, but not in the analysis of new-onset cases. Piraccini said the researchers believed the true association might lie between those results, but that is an interpretation rather than a confirmed finding.
The report says the study used online self-reports and that many users had nail problems before treatment. It does not provide enough detail here to determine how accurately participants recalled when symptoms began or how specific nail conditions were verified. Weight loss, changes in food intake, nutritional deficiencies and other health conditions may also be relevant; the source does not establish which factors explain the observed differences.
As an affiliate, we earn on qualifying purchases.
Further Study Is Planned
Piraccini said the findings would prompt the researchers to conduct more studies. Further work would need to clarify whether nail changes begin after treatment, how often they occur, and whether rates differ by medication, dose or the amount and pace of weight loss. The source material does not give a timetable for those studies.
For now, Piraccini advised clinicians treating GLP-1 users to ask whether nail problems were present before therapy and to examine affected nails. Tung said people who notice nail changes should seek assessment for common, treatable causes; the study results alone, he said, do not support stopping an otherwise beneficial medication.
As an affiliate, we earn on qualifying purchases.
Key Questions
What nail changes were more common among GLP-1 users in the study?
Users more often reported onycholysis, or separation of a nail from its nail bed, and dyschromia, meaning nail discoloration. Fragility and ridges or grooves were also reported more often.
Does the study prove GLP-1 drugs cause detached nails?
No. It found an association in analyses of reported nail problems, but the analysis of new-onset onycholysis found no difference between users and non-users. The findings do not establish causation.
How large was the study?
Researchers compared 575 GLP-1 receptor agonist users with 1,329 people with obesity and/or type 2 diabetes who had never used a GLP-1 drug. Participants were recruited in four countries.
Should someone stop a GLP-1 medication because of nail changes?
The study does not establish that the drugs caused the nail problems. Joe Tung, a physician not involved in the research, said the findings alone would not justify stopping an otherwise beneficial medication. People with nail changes can discuss them with a qualified clinician or dermatologist.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
